Bristol Myers Squibb (BMY) announced the Committee for Medicinal Products for Human Use or CHMP of the European Medicines Agency has recommended approval of Opdivo in combination with cisplatin and gemcitabine for the first-line treatment of adult patients with unresectable or metastatic urothelial carcinoma. The positive CHMP opinion is based on results from a sub-study of the CheckMate -901 trial. The European Commission will review the CHMP recommendation. The final EC decision is anticipated in June 2024.
On March 7, 2024 the FDA approved the use of Opdivo in combination with cisplatin and gemcitabine as a first-line treatment for adult patients with unresectable or metastatic urothelial carcinoma, following a Priority Review.
For More Such Health News, visit rttnews.com.
For comments and feedback contact: editorial@rttnews.com
Business News
June 12, 2026 17:14 ET Major central bank action was the focus this week in economic news. The European Central Bank became the first major central bank to move in response to the rising inflationary pressures in the backdrop of the conflict in the Middle East. In North America, the U.S. inflation and trade data as well as Canada’s central bank decision gained attention. The Chinese trade data was the main news in Asia.